PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Own experiences in estracyt treatment of oestrogen-resistant prostatic tumours
Article published in Urologia Polska 1982/35/3-4.

authors

Leszek Jeromin, Andrzej Prelich
Klinikia Urologii Instytutu Chirurgii AM w Łodzi
Dyrektor Instytutu: doc. dr med. H. Zalech p.o.
Kierownik Kliniki: dr n. med. L. Jeromin

summary

The incidence of prostatic carcinoma in men, the causes of resistance deve-loping in these tumours to hormonal treatment and therapeutic trials with Estra­cyt in cases of oestrogen-resistant prostatic carcinoma are described. Estracyt was used in the treatment of 16 patients with prostatic carcinoma with skeletal metastases resistant to female sex hormones. In 13 cases the ge­nerał condition improved and pains decreased. In 3 cases improvement was ab-sent. The drug had no detectable effect on the tumour and on urine voiding. Its tolerance was good and no side effects were otaserved.
The authors regard Estracyt as a drug warth of recommendation in advanced cases of prostatic carcinoma resistant to conventional hormonal treatment.

references

  1. Catana R., Kaufman J., Madejowicz S., Mittelman A., Murphy G. P.: Predni-mustine therapy for advanced prostate cancer. Brit. .J. Urol., 1978, 50, 29.
  2. Chrisholm G. D., O'donoghue E. P. N., Kennedy G. L.: The treatment ofestro-gen-escaped carcinoma of the prostate with extramustine phosphate. Brit. J. Urol., 1977, 49, 717.
  3. Faul P., Smiedt E., Kem R.: Die prognostische Bedeutung des zytologischen Differenzierungsgradesbeim oestrogenbenhandelten Prostata-Carcino-ma. Urologe 1978, A 17, 377.
  4. Flocks R. H.: The treatment of stage C prostatic cancer with special reference to combined surgical and radiation therapy. J. Urol., 1973, 109, 461.
  5. Fossa S. D., Fossa J., Aakrasg A.: Hormone changes in pa­tients with prostatic carcinoma during treatment with estramustine phosphate. .1. Urol., 1977, 118, 1913
  6. Jeromin L.: Leczenie chorych na raka stercza fostroliną i bromokryptyna przy kontroli stężeń testosteronu i prolaktyny w surowicy krwi. Pol. Tyg. Lek., 1980, 35, 359.
  7. Jeromin L.: Znaczenie prolaktyny we wzroście nowotworów stercza. Pol. Tyg. Lek., 1980, 35, 453.
  8. Mostofi F. K.: Grading of prostatic carcinoma. Cancer Chemother. Rep., 1975, 59, 111.
  9. Rullis I., Sfiaeffer J. A., Lilien O. M.: Incidence of prostatic carcinoma in the elderly. Urology 1975, 6, 295.
  10. Wesołowski St. Czaplicki M., Cieślak A.: Obserwacje kliniczne stoso­wania estracytu w przypadkach raka gruczołu krokowego. Pol. Przeg. Chir., 1976, 48, 69, 783.
  11. Zieliński J.: Onkologia urologiczna. PZWL, Warszawa 1977.